Related Experiment Videos
The somatostatin analog angiopeptin does not reduce chronic hypoxic pulmonary hypertension in rats
E J Sidney1, V Hampl, D P Nelson
1VA Medical Center and University of Minnesota, Minneapolis 55417, USA.
Abstract:
Angiopeptin is an analog of somatostatin-14, which has been found to inhibit cellular proliferation in several models of systemic vascular injury. As proliferation plays a major role in pulmonary hypertension, we examined the hypothesis that angiopeptin would inhibit the development of chronic hypoxic pulmonary hypertension in the rat. Angiopeptin was infused intravenously (90-100 microg/kg/day) by minipumps in 10 rats during a 3-week exposure to hypobaric hypoxia and in six normoxic rats. Normal saline was infused in six hypoxic control rats and in seven normoxic control rats. Angiopeptin produced no significant difference in mean pulmonary arterial pressure and resistance, right ventricular weight, or medial thickness of small pulmonary vessels. Vasoconstrictor responses of isolated lungs to acute hypoxia were not affected by angiopeptin. We conclude that angiopeptin, at the high intravenous dose used, does not significantly reduce the development of chronic hypoxic pulmonary hypertension in rats.
Insights
Angiopeptin, a somatostatin analog, did not prevent chronic hypoxic pulmonary hypertension in rats. This study found no significant reduction in pulmonary arterial pressure or vascular changes, even at high doses.
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Pharmacology
Background:
- Cellular proliferation is a key factor in the development of pulmonary hypertension.
- Angiopeptin, an analog of somatostatin-14, has demonstrated anti-proliferative effects in systemic vascular injury models.
Purpose of the Study:
- To investigate the potential of angiopeptin to inhibit the development of chronic hypoxic pulmonary hypertension in a rat model.
- To assess the impact of angiopeptin on pulmonary arterial pressure, vascular remodeling, and hypoxic vasoconstriction.
Main Methods:
- Rats were exposed to 3 weeks of hypobaric hypoxia.
- Angiopeptin was administered intravenously via minipumps (90-100 microg/kg/day).
- Control groups received normal saline infusions under both hypoxic and normoxic conditions.
Main Results:
- Angiopeptin treatment did not significantly alter mean pulmonary arterial pressure or resistance.
- No significant differences were observed in right ventricular weight or medial thickness of small pulmonary vessels between angiopeptin-treated and control groups.
- Angiopeptin did not affect the vasoconstrictor responses of isolated lungs to acute hypoxia.
Conclusions:
- High intravenous doses of angiopeptin did not significantly inhibit the development of chronic hypoxic pulmonary hypertension in rats.
- The findings suggest that angiopeptin is not an effective therapeutic agent for preventing or treating this condition in the studied model.
- Further research may be needed to explore alternative mechanisms or dosages if angiopeptin is to be considered for pulmonary hypertension treatment.